NVAX: Novavax, Inc. - Summary | Jitta

Novavax, Inc.

NASDAQ:NVAX

Price
$9.00
Loss Chance
49.7%
1.79JITTA SCORE
0.12%Under Jitta Line
Jitta Ranking
177 / 279
539 / 712
3,617 / 4,222
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (29)
Recent Business Performance (42)
Financial Strength (43)
Return to Shareholders (0)
Competitive Advantage (30)
Jitta Signs
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2024
Operating MarginInconsistent
Recent Business PerformanceEarning decline 99.44% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
1.79
0.12%
2.21
135.53%
3.05
149.23%
Biotechnology
5.68
30.95%
5.68
30.95%
6.36
42.63%
COMPANY DESCRIPTION
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.